RNA Stock News 7.09 05/13/2014 10:24:55 Prosensa Holding B.V.

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 11:24 AM

Prosensa Holding B.V. (RNA) 7.09 $RNA

Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
GlobeNewswire - 2 hrs 26 mins ago
Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, May 20, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its first quarter financial results and provide a corporate update.

Busy Days Ahead for Sarepta Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 11:23AM CDT
Shares of the clinical-state biotech Sarepta Therapeutics have certainly been on a wild ride over the past year. And the underlying cause of this volatility has undoubtedly been the regulatory and clinical uncertainty regarding the company's...

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Prosensa Provides Update on Drisapersen
GlobeNewswire - Thu May 01, 5:58AM CDT
Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, yesterday provided the data analysis of its second open-label extension study (DEMAND IV/DMD114349) of drisapersen in boys with Duchenne Muscular Dystrophy (DMD) during the 66 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, PA. The Company also provided an update on the drisapersen clinical program earlier this week in a letter sent to patient group representatives and clinical investigators and will present a corporate update during an investor briefing on May 1 (webcast here).

Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that it will present at the following US conferences:

Nasdaq stocks posting largest percentage increases
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Sarepta's Roller Coaster Hits a High Point
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 8:30AM CDT
Sarepta Therapeutics has been on a roller coaster over the last few months with the Food and Drug Administration telling the company last November that it had concerns about granting an accelerated approval for Sarepta's muscular dystrophy drug...

Why Sarepta Therapeutics Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sarepta Therapeutics , a clinical-stage...

The FDA Gives Sarepta Therapeutics Inc. a Way Forward: Now What?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 9:52AM CDT
Shares of the clinical-stage biopharma Sarepta Therapeutics are up over 50% this morning following a surprise announcement that the U.S. Food and Drug Administration has apparently changed its mind about accepting a New Drug Application for the...

Why Investors Need to Watch Sarepta Therapeutics Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
Sarepta is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa ...

Prosensa to Appoint Michael Wyzga to Supervisory Board
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders' meeting, scheduled for June 17, 2014.

Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...

Prosensa Rises on Encouraging Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:20PM CDT
Shares of Prosensa rose following the announcement of encouraging data from a phase II study on drisapersen.

Prosensa rises on new data
at Investor's Business Daily - Tue Mar 18, 5:18PM CDT
The biotech shares rose 3.9% to 7.02 after the company released new data from a follow-up to a study of its Duchenne muscular dystrophy candidate late Mon. In Sept., Prosensa (RNA) said that after the initial treatment, the benefit of the drug failed...

Prosensa Muscular Dystrophy Data Send Stock Rising
at Investor's Business Daily - Tue Mar 18, 11:50AM CDT
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a...

Prosensa Making the Best of Inconsistent Drisapersen Data
at The Street - Tue Mar 18, 10:03AM CDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.

Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...

Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments
Thomson Reuters ONE - Tue Mar 18, 6:01AM CDT
Prosensa Committed to Defining a Path Forward for Its Lead Product, Drisapersen

Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys
GlobeNewswire - Mon Mar 17, 5:00PM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZKH and Intel Launch Industrial AI Model at the Edge

Industrial Revolution at the Edge Forget the horseless carriage; this time, we're talking about AI stepping onto the factory floor in China. ZKH Group Limited has spun a new yarn in MRO with its AI subsidiary, LingLong Intelligence, partnering up with tech giant Intel to launch the LingLong Insight 1.0. The venue was Intel Connection 2026 in Suzhou, China, where this...

Hudsonville's Leadership Shift Eyes the Future

Hudsonville's New Chapter: Enter CJ Ellens When a firm as storied as Hudsonville Ice Cream elects a new captain at the helm, folks sit up and take notice. CJ Ellens, already well-embedded in the fabric of Hudsonville, is set to steer the ship starting January 1, 2027. This isn't just a revolving door of C-suites, but more like a passing of the torch to someone bred in the...

Endeavor & GoPath's Game-Changing Cancer Test Launch

Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...

PRA Group Marks 30 Years with Nasdaq Bell Ringing

A Milestone in Times Square Thirty trips around the sun, and here we are: PRA Group, the change-maker in the world of nonperforming loans, is celebrating by ringing the Nasdaq Opening Bell. It's a pretty big to-do in the financial world to get this nod, standing out in New York City's Times Square, no less. This shindig showcased Martin Sjolund, their President and CEO,...

Latitude Expands Food Allergy Care to Long Island

New Clinic Brings Specialized Care to Long Island Listen, when it comes to healthcare, especially something as life-altering as food allergies, you're not just looking for any run-of-the-mill clinic. You're looking for the right place with the right people who get it. And folks in Long Island are getting something worth celebrating—a new clinic from Latitude Food...

Potomac Edison Targets Virginia Grid Revamp by 2030

Strengthening the Backbone of Virginia's Power Supply Ever had your lights flicker on a windy day and wondered if the power grid would hold? Potomac Edison, under the banner of FirstEnergy Corp., is stepping up with a game plan to fortify the electric spine of Virginia and its neighbors. They're diving into a multi-state adventure, rebuilding and erecting 138 kV...

Bird-X Welcomes Doolittle to Elevate Sales Strategy

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Tripo AI's New Canvas Redefines 3D Workflow Process

Rethinking 3D Content Creation Well, well, well, Tripo AI is shaking things up in the 3D world with its new Agentic Canvas. This isn't just another gizmo to throw in the digital drawer; it's a tool looking to flip the whole 3D game on its head. Picture taking complex 3D workflows and molding them like clay into something that’s efficient and scalable. That’s what...

Tim Brewer Leads AXA XL's Growth in Commercial Bonds

AXA XL Welcomes a New Leader You know, insurance isn't exactly what sets hearts racing, but there's something intriguing about the chess game of leadership changes. AXA XL's latest move? They’ve roped in Tim Brewer to helm their Commercial Bonds for the Americas. A hefty role, sure, but one that comes with its fair share of high-stakes pressure. Kind of like betting on...

DriveNets' Big Role at FYUZ 26: AI Fabrics Spotlighted

Networking Titans Gather at FYUZ 26 Alright, folks, mark the first week of November as a field day for telecom and AI networking enthusiasts. DriveNets, a seasoned player in large-scale networking, is joining forces with some of the industry's giants—AT&T, KDDI, and Broadcom—at the Telecom Infra Project's flagship event, FYUZ 26, unfolding at The Westin Seattle. From...